相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape
Neeraja Dharmaraj et al.
ONCOIMMUNOLOGY (2019)
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial
Paolo A. Ascierto et al.
JAMA ONCOLOGY (2019)
Patient value: Perspectives from the advocacy community
Bonnie J. Addario et al.
HEALTH EXPECTATIONS (2018)
Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols The SPIRIT-PRO Extension
Melanie Calvert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2018)
Patient-reported outcomes in PD-1/PD-L1 inhibitor registration trials: FDA analysis of data submitted and future directions.
Lynn Jackson Howie et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3]
Darius N. Lakdawalla et al.
VALUE IN HEALTH (2018)
A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7]
Louis P. Garrison et al.
VALUE IN HEALTH (2018)
ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients
Eleanor M. Perfetto
VALUE IN HEALTH (2018)
Patient Access to Medicines for Rare Diseases in European Countries
Andreja Deticek et al.
VALUE IN HEALTH (2018)
Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group
Sandra Nestler-Parr et al.
VALUE IN HEALTH (2018)
Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6]
Richard J. Willke et al.
VALUE IN HEALTH (2018)
DIFFERENTIATION OF HEALTH-RELATED QUALITY OF LIFE OUTCOMES BETWEEN FIVE DISEASE AREAS: RESULTS FROM AN INTERNATIONAL SURVEY OF PATIENTS
Olina Efthymiadou et al.
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE (2018)
Future Directions for Cost-effectiveness Analyses in Health and Medicine
Peter J. Neumann et al.
MEDICAL DECISION MAKING (2018)
Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
Sunilkumar Kakadia et al.
ONCOTARGETS AND THERAPY (2018)
Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology A Systematic Review and Quantitative Analysis
Bruno Kovic et al.
JAMA INTERNAL MEDICINE (2018)
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia
Melanie D. Whittington et al.
JAMA PEDIATRICS (2018)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens et al.
EUROPEAN JOURNAL OF CANCER (2017)
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment
Ethan Basch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Value to Whom? The Patient Voice in the Value Discussion
Eleanor M. Perfetto et al.
VALUE IN HEALTH (2017)
Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks
Joshua T. Cohen et al.
VALUE IN HEALTH (2017)
Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs
Tanya G. K. Bentley et al.
VALUE IN HEALTH (2017)
Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review
Da-Ping Yu et al.
ONCOLOGY LETTERS (2017)
The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Immune Checkpoint Inhibitors in Challenging Populations
Douglas B. Johnson et al.
CANCER (2017)
Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC.
Luis A. Diaz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management
Frank Kroschinsky et al.
CRITICAL CARE (2017)
QALYs as a measure of value in cancer
Nancy J. Devlin et al.
JOURNAL OF CANCER POLICY (2017)
Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients
Vakaramoko Diaby et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives
Markus Moehler et al.
EUROPEAN JOURNAL OF CANCER (2016)
Doxorubicin and cisplatin induce apoptosis in ovarian stromal cells obtained from cryopreserved human ovarian tissue
Raffaella Fabbri et al.
FUTURE ONCOLOGY (2016)
Toward a Patient-Centered Value Framework in Oncology
Ethan Basch
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards
Andrew Bottomley et al.
LANCET ONCOLOGY (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them
Kerry J. Savage et al.
EXPERT REVIEW OF HEMATOLOGY (2016)
Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy
Klaus Okkenhaug et al.
CANCER DISCOVERY (2016)
The evaluation of immunotherapy and chemotherapy treatment on melanoma: a network meta-analysis
BaSang CiRen et al.
ONCOTARGET (2016)
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC
Matthew David Hellmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Continuous Patient Engagement in Comparative Effectiveness Research
C. Daniel Mullins et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
J. Jaime Caro et al.
MEDICAL DECISION MAKING (2012)
Defining Comparative Effectiveness Research The Importance of Getting It Right
Harold C. Sox
MEDICAL CARE (2010)
Using real-world data for coverage and payment decisions: The ISPOR real-world data task force report
Louis P. Garrison et al.
VALUE IN HEALTH (2007)
分享论文
